Denosumab for Osteoporosis Treatment in Rheumatic Diseases: What Do We Know 15 Years Post Approval?

2025/08/01 by Stanley Cohen, Kenneth G. Saag · 1 voice
Biochemistry, Genetics and Molecular Biology · Medicine · #Bone Metabolism and Diseases #Bone health and osteoporosis research #Bone health and treatments

paper · pdf · doi:10.3899/jrheum.2025-0726

openalex publication_date 2025/08/01 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/31

Abstract

Denosumab was approved for the treatment of postmenopausal patients with osteoporosis (OP) at high risk of fracture in 2010. This journey to approval was the result of extensive preclinical work in the 1990s demonstrating the role of the tumor necrosis factor (TNF) superfamily of proteins, namely receptor activator of nuclear factor-kB (RANK) and RANK ligand (RANKL), in the generation of activated mature osteoclasts from hematopoietic osteoclast progenitors.¹

Discussions

• Editorial Denosumab for Osteoporosis Treatment in Rheumatic Diseases: What Do We Know 15 Years Post Approval? 📖 doi.org/10.3899/jrhe... #denosumab #osteoporosis [bsky, 1 points, 0 comments]

Related

• Effects of denosumab on bone turnover markers in postmenopausal osteoporosis
• Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures
• RANK-Ligand inhibitor associated osteonecrosis of the jaw
• Minireview: The OPG/RANKL/RANK System
• The Effect of Denosumab on Risk for Emergently Treated Hypocalcemia by Stage of Chronic Kidney Disease